Overview

FOLFOX6 Totally Neoadjuvant Chemoradiation Therapy in Locally Advanced Rectal Cancer: A Real World Study

Status:
Recruiting
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
Preoperative 5FU based chemoradiotherapy is still the standard of treatment for locally advanced rectal cancer. About 15-20% of patients would achieve pathologic complete response (pCR) after neoadjuvant CRT, and the survival outcome was much better than that of non-pCR. Total neoadjuvant treatment had been evaluated a lot in recent years, including induction chemotherapy or consolidation chemotherapy, or concurrent chemoradiotherapy. We aimed to evaluated the safety and efficacy of total neoadjuvant treatemnt in locally advanced rectal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-sen University
Treatments:
Fluorouracil
Leucovorin
Oxaliplatin